ReviewExpert opinion on drug delivery2010
The use of single chain Fv as targeting agents for immunoliposomes: an update on immunoliposomal drugs for cancer treatment.
Review in Expert opinion on drug delivery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 87 citations in OpenAlex.
- Biomimetic phosphorus dendrimer multi-epitope nanovaccine enhances humoral and cellular immune response against African swine fever virus.Journal of nanobiotechnology · 2025Article
- The modification of conventional liposomes for targeted antimicrobial delivery to treat infectious diseases.Discover nano · 2025Review
- A Holographic-Type Model in the Description of Polymer-Drug Delivery Processes.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Photoactive imaging and therapy for colorectal cancer using a CEA-Affimer conjugated Foslip nanoparticle.Nanoscale · 2024Article
- Strategies for Non-Covalent Attachment of Antibodies to PEGylated Nanoparticles for Targeted Drug Delivery.International journal of nanomedicine · 2024Review
- Article
- Anti-HER2 Super Stealth Immunoliposomes for Targeted-Chemotherapy.Advanced healthcare materials · 2023Article
- Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.Advanced drug delivery reviews · 2021Review
- An overview on the investigation of nanomaterials' effect on plasma components: immunoglobulins and coagulation factor VIII, 2010-2020 review.Nanoscale advances · 2021Review
- Polymeric Nanocarriers of Drug Delivery Systems in Cancer Therapy.Pharmaceutics · 2020Review
- Nanogel: A Versatile Nano-Delivery System for Biomedical Applications.Pharmaceutics · 2020Review
- Impacting Pancreatic Cancer Therapy in HeterotypicNano letters · 2019Article
- Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting.PloS one · 2019Article
- Liposomes targeted to MHC-restricted antigen improve drug delivery and antimelanoma response.International journal of nanomedicine · 2019Article
- A Highly Sensitive Detection System based on Proximity-dependent Hybridization with Computer-aided Affinity Maturation of a scFv Antibody.Scientific reports · 2018Article
- Lung Cancer-Targeting Peptides with Multi-subtype Indication for Combinational Drug Delivery and Molecular Imaging.Theranostics · 2017Article
- Antibody fragments as nanoparticle targeting ligands: a step in the right direction.Chemical science · 2017Article
- Article
- In Vivo Targeted MR Imaging of Endogenous Neural Stem Cells in Ischemic Stroke.Molecules (Basel, Switzerland) · 2016Article
- Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
importance of the fieldTargeted liposomal drugs represent the next evolution of liposomal drug delivery in cancer treatment. In various preclinical cancer models, antibody-targeted PEGylated liposomal drugs have demonstrated superior therapeutic effects over their non-targeted counterparts. Single chain Fv (scFv) has gained popularity in recent years as the targeting agent of choice over traditional targeting agents such as monoclonal antibodies (mAb) and antibody fragments (e.g., Fab'). AREAS COVERED IN THIS REVIEW: This review is focused mainly on advances in scFv-targeted liposomal drug delivery for the treatment of cancers, based on a survey of the recent literature, and on experiments done in a murine model of human B-lymphoma, using anti-CD19 targeted liposomes targeted with whole mAb, Fab' fragments and scFv fragments. WHAT THE READER WILL GAIN: This review examines the recent advances in PEGylated immunoliposomal drug delivery, focusing on scFv fragments as targeting agents, in comparison with Fab' and mAb. TAKE HOME MESSAGE: For clinical development, scFv are potentially preferred targeting agents for PEGylated liposomes over mAb and Fab', owing to factors such as decreased immunogenicity, and pharmacokinetics/biodistribution profiles that are similar to non-targeted PEGylated (Stealth) liposomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.